Literature DB >> 26646187

Comparative Analysis of Tunical Plication vs. Intralesional Injection Therapy for Ventral Peyronie's Disease.

Faysal A Yafi1, Georgios Hatzichristodoulou2, Christopher J Knoedler1, Landon W Trost3, Suresh C Sikka1, Wayne J G Hellstrom1.   

Abstract

INTRODUCTION: Approximately 10% of Peyronie's disease (PD) patients present with ventral curvatures and, as such, there is a paucity of data describing the optimal approach for treatment. AIM: This study aims to compare the outcomes of surgery (tunical plication [TP]) and intralesional injection (ILI) therapy (interferon-α2b) in men with ventral PD.
MATERIALS AND METHODS: Retrospective data were collected from two centers: Tulane University (ILI) and Technical University of Munich (TP). Collected variables included patient demographics, pre- and post-treatment sexual function, rigorous penile measurements (curvature, length, and penile vascular findings), and post-treatment outcomes.
RESULTS: A total of 35 patients with ventral PD (21 ILI and 14 TP) were included in the study. There were no significant differences between the two groups prior to the interventions. There was a significantly better improvement in mean curvature with TP (46.4 degrees) as compared with ILI (9.3), P < 0.0001. TP was also associated with a significantly higher rate of ≥20% improvement in curvature as compared with ILI (100% vs. 67%, P = 0.027). Although there was no significant difference in post-treatment change in Sexual Health Inventory for Men (SHIM) scores between the groups, 36% of the ILI patients noted an improved SHIM score as compared with none in the TP group. Erect penile length was preserved or improved in 67% of the ILI group vs. 14% of the TP group, P = 0.005.
CONCLUSIONS: TP confers a better overall improvement in penile curvature as compared with ILI in patients with ventral PD. Preserved or improved erect penile length and SHIM scores may be observed in patients undergoing ILI. 12:2492-2498.
© 2015 International Society for Sexual Medicine.

Entities:  

Keywords:  Interferon α2b; Intralesional Injection; Peyronie's Disease; Tunical Plication; Ventral Curvature; Ventral Plaque

Mesh:

Substances:

Year:  2015        PMID: 26646187     DOI: 10.1111/jsm.13072

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  5 in total

Review 1.  Collagenase Clostridium Histolyticum in the Treatment of Peyronie's Disease: Review of a Minimally Invasive Treatment Option.

Authors:  Andrew T Gabrielson; Laith M Alzweri; Wayne Jg Hellstrom
Journal:  World J Mens Health       Date:  2017-09-06       Impact factor: 5.400

2.  Penile Plication With or Without Degloving of the Penis Results in Similar Outcomes.

Authors:  Rustam Kadirov; Burhan Coskun; Onur Kaygisiz; Kadir Omur Gunseren; Yakup Kordan; Ismet Yavascaoglu; Hakan Kilicarslan
Journal:  Sex Med       Date:  2017-07-13       Impact factor: 2.491

3.  How Atypical Penile Curvature Influence Clinical Outcomes in Patients with Peyronie's Disease Receiving Collagenase Clostridium Histolyticum Therapy?

Authors:  Andrea Cocci; Fabrizio Di Maida; Giorgio Ivan Russo; Marina Di Mauro; Gianmartin Cito; Marco Falcone; Andrea Minervini; Giovanni Cacciamani; Riccardo Campi; Andrea Mari; Francesco Sessa; Nicola Mondaini
Journal:  World J Mens Health       Date:  2019-05-29       Impact factor: 5.400

4.  Trends in treatment of Peyronie's disease in adult men in the United States from 2008 to 2017-results from an encounter and claims database.

Authors:  Odinachi I Moghalu; Rupam Das; Joshua Horns; Alexander Campbell; James M Hotaling; Alexander W Pastuszak
Journal:  Int J Impot Res       Date:  2021-04-07       Impact factor: 2.408

Review 5.  Collagenase Clostridium histolyticum in the treatment of Peyronie's disease: patient selection and perspectives.

Authors:  Paige K Kuhlmann; Kenneth J DeLay; James Anaissie; Wayne Jg Hellstrom; Faysal A Yafi
Journal:  Patient Prefer Adherence       Date:  2017-03-02       Impact factor: 2.711

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.